BiomEdit Receives Environment Clearance for BE-101
Slice of Agriculture Team
11/14/2025
Key highlights
- FONSI letter received from USDA for BE-101
- First non-antibiotic biologic for necrotic enteritis
- Field safety trials to start in early Q1 2026
Source: PR Newswire
Notable Quote
“ The FONSI letter represents another key regulatory milestone as we work to deliver a first-of-its-kind solution for poultry producers. ”
Aaron Schacht, CEO at BiomEdit
Why this matters
This announcement signifies a major step forward in the development of non-antibiotic solutions for poultry health, addressing a critical need in the industry while advancing BiomEdit's commercialization plans. This development is particularly significant for the agriculture sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
